The impact of exogenous CO releasing molecule CORM‑2 on inflammation and signaling of orthotopic lung cancer

Shao,Li; Liu,Congyang; Wang,Shuhua; Liu,Jiannan; Wang,Li; Lv,Liping; Zou,Yong

doi:10.3892/ol.2018.9022

The impact of exogenous CO releasing molecule CORM‑2 on inflammation and signaling of orthotopic lung cancer

Authors:
- Li Shao
- Congyang Liu
- Shuhua Wang
- Jiannan Liu
- Li Wang
- Liping Lv
- Yong Zou
View Affiliations

Affiliations: Department of Integrated Traditional Chinese and Western Medicine, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P.R. China, Department of Information, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P.R. China, Department of Medical Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P.R. China
Published online on: June 26, 2018 https://doi.org/10.3892/ol.2018.9022
Pages: 3223-3230

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to evaluate the therapeutic effect of CO‑releasing molecule‑2 (CORM‑2) in an established mouse orthotopic lung cancer model and investigate the underlying mechanism associated with inflammation pathway. A total of 80 mice were randomly divided into two groups with 20 serving as a normal control and 60 used for the orthotopic lung cancer model. The tumor group was either untreated, or administrated with DMSO or CORM‑2. The mice were sacrificed at day 7 and 14 post‑treatment, and the body weight, and thymus and spleen indices were determined. Pathological analysis was performed with hematoxylin and eosin (HE) staining. Serous inflammatory factors were measured using an ELISA. The expression levels of eukaryotic translation initiation factor 4E, p70S6K and toll‑like receptor‑4 (TLR4) were quantified by reverse transcription‑polymerase chain reaction. The effects of CORM‑2 on the phosphoinositide 3‑kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR), TLR4/nuclear factor (NF)‑κB signaling pathways were determined by western blotting. The body weight increased over time in the control group, while it significantly declined in tumor‑bearing mice (P<0.05). CORM‑2 treatment significantly increased body weight in comparison with the model and DSMO treatment groups (P<0.05). The thymus and spleen indices both reduced in the model and DMSO treatment groups, which was significantly rescued with CORM‑2 administration (P<0.05). The HE staining results demonstrated few nodule formations, fibrous hyperplasia and extensive necrosis, which suggested overt inhibitory effects against cancer of CORM‑2. The serous contents of tumor necrosis factor‑α, interleukin (IL)‑1β and IL‑6 in the CORM‑2 group was significantly lower compared with that in the model and DMSO groups (P<0.05). The ratio of phosphorylated (p‑PI3K/PI3K, p‑AKT/AKT, p‑mTOR/mTOR, p‑NF‑κB‑p65/NF‑κB‑p65 and expression of TLR4 significantly decreased in the CORM‑2 group compared with the model and DMSO groups (P<0.05). To the best of our knowledge, the data in the present study demonstrated in vivo for the first time, the therapeutic potential of the CORM complex, which is associated with suppression of inflammation and general protein synthesis.

View Figures

View References

1	Lei L, Huang Y and Gong W: miR-205 promotes the growth, metastasis and chemoresistance of NSCLC cells by targeting PTEN. Oncol Rep. 30:2897–2902. 2013. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
3	Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current therapies and new targeted treatments. Lancet. 389:299–311. 2017. View Article : Google Scholar : PubMed/NCBI
4	Rabe KF: Lung cancer staging: A true story. Lancet Respir Med. 3:258–259. 2015. View Article : Google Scholar : PubMed/NCBI
5	Zalcman G, Bergot E, Creveuil C, Levallet G and Lechapt E: Integrating biomarkers into clinical trials: Methodological issues for a new paradigm in nonsmall cell lung cancer. Curr Opin Oncol. 23:106–111. 2011. View Article : Google Scholar : PubMed/NCBI
6	Baranov VS, Glotov OS and Baranova EV: Genetic and epigenetic news in gerontology. Adv Gerontol. 27:247–256. 2014.PubMed/NCBI
7	Tartour E and Zitvogel L: Lung cancer: Potential targets for immunotherapy. Lancet Respir Med. 1:551–563. 2013. View Article : Google Scholar : PubMed/NCBI
8	National Lung Screening Trial Research Team, . Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM and Sicks JD: Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 365:395–409. 2011. View Article : Google Scholar : PubMed/NCBI
9	Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P, Mitchell A, Bolejack V, et al: The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming (Eighth) Edition of the TNM classification for lung cancer. J Thorac Oncol. 11:39–51. 2016. View Article : Google Scholar : PubMed/NCBI
10	Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Rosenthal SA, Gore E, et al: Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: Randomized phase III trial RTOG 9410. J Natl Cancer Inst. 103:1452–1460. 2011. View Article : Google Scholar : PubMed/NCBI
11	Tsao AS, Scagliotti GV, Bunn PA Jr, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, et al: Scientific advances in lung cancer 2015. J Thorac Oncol. 11:613–638. 2016. View Article : Google Scholar : PubMed/NCBI
12	Douglas CG, Haldane JS and Haldane JB: The laws of combination of haemoglobin with carbon monoxide and oxygen. J Physiol. 44:275–304. 1912. View Article : Google Scholar : PubMed/NCBI
13	Boehning D and Snyder SH: Circadian rhythms. Carbon monoxide and clocks. Science. 298:2339–2340. 2002. View Article : Google Scholar : PubMed/NCBI
14	Zhuo M, Small SA, Kandel ER and Hawkins RD: Nitric oxide and carbon monoxide produce activity-dependent long-term synaptic enhancement in hippocampus. Science. 260:1946–1950. 1993. View Article : Google Scholar : PubMed/NCBI
15	Kobayashi A, Ishikawa K, Matsumoto H, Kimura S, Kamiyama Y and Maruyama Y: Synergetic antioxidant and vasodilatory action of carbon monoxide in angiotensin II-induced cardiac hypertrophy. Hypertension. 50:1040–1048. 2007. View Article : Google Scholar : PubMed/NCBI
16	Durante W, Johnson FK and Johnson RA: Role of carbon monoxide in cardiovascular function. J Cell Mol Med. 10:672–686. 2006. View Article : Google Scholar : PubMed/NCBI
17	Nakahira K and Choi AM: Carbon monoxide in the treatment of sepsis. Am J Physiol Lung Cell Mol Physiol. 309:L1387–L1393. 2015. View Article : Google Scholar : PubMed/NCBI
18	Akamatsu Y, Haga M, Tyagi S, Yamashita K, Graça-Souza AV, Ollinger R, Czismadia E, May GA, Ifedigbo E, Otterbein LE, et al: Heme oxygenase-1-derived carbon monoxide protects hearts from transplant associated ischemia reperfusion injury. FASEB J. 18:771–772. 2004. View Article : Google Scholar : PubMed/NCBI
19	Nakamura K and Smyth MJ: Targeting cancer-related inflammation in the era of immunotherapy. Immunol Cell Biol. 95:325–332. 2017. View Article : Google Scholar : PubMed/NCBI
20	Azaro A, Rodon J, Calles A, Braña I, Hidalgo M, Lopez-Casas PP, Munoz M, Westwood P, Miller J, Moser BA, et al: A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. Invest New Drugs. 33:710–719. 2015. View Article : Google Scholar : PubMed/NCBI
21	Chung YH and Kim D: Enhanced TLR4 expression on colon cancer cells after chemotherapy promotes cell survival and epithelial-mesenchymal transition through phosphorylation of GSK3β. Anticancer Res. 36:3383–3394. 2016.PubMed/NCBI
22	Mundi PS, Sachdev J, McCourt C and Kalinsky K: AKT in cancer: New molecular insights and advances in drug development. Br J Clin Pharmacol. 82:943–956. 2016. View Article : Google Scholar : PubMed/NCBI
23	Rinkenbaugh AL and Baldwin AS: The NF-kB pathway and cancer stem cells. Cells. 5:E162016. View Article : Google Scholar : PubMed/NCBI
24	Motterlini R and Otterbein LE: The therapeutic potential of carbon monoxide. Nat Rev Drug Discov. 9:728–743. 2010. View Article : Google Scholar : PubMed/NCBI
25	Tenhunen R, Marver HS and Schmid R: The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci USA. 61:748–755. 1968. View Article : Google Scholar : PubMed/NCBI
26	Dercho RA, Nakatsu K, Wong RJ, Stevenson DK and Vreman HJ: Determination of in vivo carbon monoxide production in laboratory animals via exhaled air. J Pharmacol Toxicol Methods. 54:288–295. 2006. View Article : Google Scholar : PubMed/NCBI
27	Foresti R, Bani-Hani MG and Motterlini R: Use of carbon monoxide as a therapeutic agent: promises and challenges. Intensive Care Med. 34:649–658. 2008. View Article : Google Scholar : PubMed/NCBI
28	Motterlini R, Clark JE, Foresti R, Sarathchandra P, Mann BE and Green CJ: Carbon monoxide-releasing molecules: Characterization of biochemical and vascular activities. Circ Res. 90:E17–E24. 2002. View Article : Google Scholar : PubMed/NCBI
29	Xie J, Wang X and Proud CG: mTOR inhibitors in cancer therapy. F1000Res. 5:F1000 Faculty Rev. –2078E. 2016. View Article : Google Scholar : PubMed/NCBI
30	Crusz SM and Balkwill FR: Inflammation and cancer: Advances and new agents. Nat Rev Clin Oncol. 12:584–596. 2015. View Article : Google Scholar : PubMed/NCBI
31	Cho WC, Kwan CK, Yau S, So PP, Poon PC and Au JS: The role of inflammation in the pathogenesis of lung cancer. Expert Opin Ther Targets. 15:1127–1137. 2011. View Article : Google Scholar : PubMed/NCBI
32	Wang R, Ganesan S and Zheng XF: Yin and yang of 4E-BP1 in cancer. Cell Cycle. 15:1401–1412. 2016. View Article : Google Scholar : PubMed/NCBI
33	Riedl A, Schlederer M, Pudelko K, Stadler M, Walter S, Unterleuthner D, Unger C, Kramer N, Hengstschläger M, Kenner L, et al: Comparison of cancer cells in 2D vs. 3D culture reveals differences in AKT-mTOR-S6K signaling and drug responses. J Cell Sci. 130:203–218. 2017. View Article : Google Scholar : PubMed/NCBI